SCHEMBL565533

SCHEMBL565533

CC(C)CN(Cc1cc2c(cc1Cl)OCCCO2)C(=O)C(C)CNCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PROKR2 Q8NFJ6 3/20 0.56
RAB9A P51151 7/20 0.43
NPC1 O15118 6/20 0.43
ALDH1A1 P00352 7/20 0.42
SMN1; SMN2 Q16637 6/20 0.39
HPGD P15428 4/20 0.39
KDM4E B2RXH2 3/20 0.37
HSD17B10 Q99714 2/20 0.37
MEN1 O00255 1/20 0.37
RECQL P46063 1/20 0.37
KMT2A Q03164 1/20 0.37
TSHR P16473 3/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 3/20 0.36
EIF4E P06730 1/20 0.35
USP2 O75604 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL565524 0.87 PROKR2 (0.69) PROKR2RAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL565109 0.87 PROKR2 (0.69) PROKR2RAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL15693909 0.87 PROKR2 (0.69) PROKR2RAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL565257 0.87 PROKR2 (0.53) PROKR2RAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL565086 0.85 PROKR2 (0.54) PROKR2RAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL565087 0.84 PROKR2 (0.65) PROKR2RAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL565739 0.84 PROKR2 (0.55) PROKR2RAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL564225 0.82 PROKR2 (0.67) PROKR2RAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL564098 0.81 PROKR2 (0.57) PROKR2RAB9AALDH1A1SMN1; SMN2HPGD
SCHEMBL565217 0.81 PROKR2 (0.57) PROKR2RAB9ANPC1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722896-B2 Prokineticin receptor antagonists and uses thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-05-13 US disclosed
US-8722896-B2 Prokineticin receptor antagonists and uses thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-05-13 US disclosed
US-8722896-B2 Prokineticin receptor antagonists and uses thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-05-13 US disclosed
US-20120035149-A1 Prokineticin Receptor Antagonists And Uses Thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-02-09 US disclosed
US-20120035149-A1 Prokineticin Receptor Antagonists And Uses Thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-02-09 US disclosed
US-20120035149-A1 Prokineticin Receptor Antagonists And Uses Thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-02-09 US disclosed
WO-2010077976-A2 PROKINETICIN RECEPTOR ANTAGONISTS AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035149-A1 Prokineticin Receptor Antagonists And Uses Thereof PROKR2, PROKR1, GIPR PROKR2 1/4885RAB9A 1704/4885NPC1 3472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.